v3.26.1
Note 11 - Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2026
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

 

 

 

 

 

Number of

 

 

Average

 

 

Contractual

 

 

Intrinsic

 

 

 

Stock Options

 

 

Exercise Price

 

 

Term (Years)

 

 

Value(2)

 

Outstanding stock options at December 31, 2025

 

 

10,272,642

 

 

$

1.62

 

 

 

7.5

 

 

$

396

 

Granted(1)

 

 

2,448,500

 

 

$

1.33

 

 

 

 

 

 

 

 

 

Exercised

 

 

(15,949

)

 

$

1.29

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(380,698

)

 

$

1.39

 

 

 

 

 

 

 

 

 

Outstanding stock options at June 30, 2026(3)

 

 

12,324,495

 

 

$

1.57

 

 

 

7.1

 

 

$

363

 

Vested and exercisable stock options at June 30, 2026

 

 

8,186,559

 

 

$

1.70

 

 

 

6.1

 

 

$

343

 

Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]

 

 

 

 

 

 

Weighted

 

 

 

Number of

 

 

Average

 

 

 

Restricted

 

 

Grant Date

 

 

 

Stock Awards

 

 

Fair Value

 

Unvested restricted stock awards as of December 31, 2025

 

 

6,584,240

 

 

$

4.02

 

Granted

 

 

5,746,000

 

 

 

1.36

 

Vested

 

 

(20,622

)

 

 

1.49

 

Forfeited

 

 

(14,378

)

 

 

1.49

 

Unvested restricted stock awards as of June 30, 2026

 

 

12,295,240

 

 

$

2.78

 

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Lucid Diagnostics 2018 Equity Plan – cost of revenue

 

$

14

 

 

$

38

 

 

$

127

 

 

$

71

 

Lucid Diagnostics 2018 Equity Plan – sales and marketing

 

 

336

 

 

 

245

 

 

 

589

 

 

 

466

 

Lucid Diagnostics 2018 Equity Plan - general and administrative

 

 

1,166

 

 

 

740

 

 

 

2,070

 

 

 

1,341

 

Lucid Diagnostics 2018 Equity Plan - research and development

 

 

165

 

 

 

119

 

 

 

296

 

 

 

214

 

PAVmed 2014 Equity Plan - cost of revenue

 

 

 

 

 

 

 

 

1

 

 

 

38

 

PAVmed 2014 Equity Plan - sales and marketing

 

 

2

 

 

 

 

 

 

4

 

 

 

19

 

PAVmed 2014 Equity Plan - general and administrative

 

 

3

 

 

 

1

 

 

 

5

 

 

 

1

 

PAVmed 2014 Equity Plan - research and development

 

 

8

 

 

 

 

 

 

12

 

 

 

24

 

Total stock-based compensation expense

 

$

1,694

 

 

$

1,143

 

 

$

3,104

 

 

$

2,174

 

Schedule of Unrecognized Compensation Expense by Plan [Table Text Block]

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Remaining

 

 

 

Unrecognized

 

 

Service Period

 

 

 

Expense

 

 

(Years)

 

Lucid Diagnostics 2018 Equity Plan

 

 

 

 

 

 

 

 

Stock Options

 

$

3,118

 

 

 

2.0

 

Restricted Stock Awards

 

$

9,341

 

 

 

2.4

 

PAVmed 2014 Equity Plan

 

 

 

 

 

 

 

 

Stock Options

 

$

26

 

 

 

2.2

 

Restricted Stock Awards

 

$

98

 

 

 

2.8

 

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

Expected term of stock options (in years)

 

 

5.8

 

 

 

5.8

 

Expected stock price volatility

 

 

67

%

 

 

68

%

Risk free interest rate

 

 

3.8

%

 

 

4.4

%

Expected dividend yield

 

 

%

 

 

%